 |
|
|
| |
Influence of Hepatitis C Virus (HCV) Genotype-1 (G1) Subtype, Baseline Viral Load and IL28B Genotype on Peginterferon (PEG-IFN)/Ribavirin (RBV) Treatment Response: Results of the IDEAL Study
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
A. Rabiee1, H. Tillmann2, F. Poordad3, E.J. Lawitz4, M.L. Shiffman5, A.J. Muir2, S. Noviello6, C.A. Brass6, L.D. Pedicone6, J.K. Albrecht6, M.S. Sulkowski1, I. Jacobson7
1Johns Hopkins University, Baltimore, MD, U.S.A.; 2Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, U.S.A.; 3Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A.; 4Alamo Medical Research, San Antonio, TX, U.S.A.; 5Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA, U.S.A.; 6Merck, Sharp, & Dohme, Corp., Whitehouse Station, NJ, U.S.A.; 7Weill Cornell Medical College, New York, NY, U.S.A.
|
| |
|
|
|
|
|
